| Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia (NCT05246345) | University Hospital, Clermont-Ferrand | 2022-03-07 |
| Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients (NCT04640909) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2021-10-01 |
| A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. (NCT04923048) | Genor Biopharma Co., Ltd. | 2021-08-31 |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia (NCT04806035) | TG Therapeutics, Inc. | 2021-04-28 |
| The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19 (NCT04746092) | Tel-Aviv Sourasky Medical Center | 2021-01-06 |
| CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD. (NCT04639362) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2020-12-29 |
| A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (NCT04694560) | Memorial Sloan Kettering Cancer Center | 2020-12-22 |
| Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia (NCT04512105) | University of California, Irvine | 2020-12-02 |
| Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL (NCT03639324) | Virginia Commonwealth University | 2020-10-02 |
| Hypertension Management in Cancer Patients (NCT03919214) | Duke University | 2019-12-10 |
| Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment (NCT03868722) | Rigshospitalet, Denmark | 2019-10-11 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (NCT03997968) | Cyteir Therapeutics, Inc. | 2019-10-09 |
| A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia (NCT04016636) | Mela Osorio Maria Jose | 2019-08-12 |
| Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL (NCT03572634) | Sumitomo Pharma America, Inc. | 2019-06-10 |
| Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia (NCT05316831) | Region Örebro County | 2019-01-01 |
| Study of the Metabolism in the Lymphatic Niche of CLL (NCT05610228) | Centre Hospitalier Universitaire de Nice | 2018-11-07 |
| Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL (NCT03524235) | Noah Merin | 2018-07-18 |
| Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL (NCT03283137) | University of Chicago | 2018-01-23 |
| Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome (NCT03113695) | University of California, San Diego | 2017-12-20 |
| Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study (NCT03231579) | Carevive Systems, Inc. | 2017-07-21 |
| Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia (NCT02828774) | Assuta Medical Center | 2016-08-01 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (NCT02362035) | Acerta Pharma BV | 2015-02-20 |
| Heavy Light Chain in Chronic Lymphocytic Leukemia (NCT02377869) | Bnai Zion Medical Center | 2015-01-01 |
| A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) (NCT02229422) | University of California, San Diego | 2014-09-01 |
| Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) (NCT02046928) | Ångstrom Pharmaceuticals | 2014-02-01 |
| Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients (NCT01862445) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2013-10-01 |
| Registry of the German CLL Study Group (NCT02863692) | German CLL Study Group | 2013-08-01 |
| Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL (NCT01703364) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2012-06-01 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives (NCT01532635) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-03-01 |
| Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL (NCT01465334) | Dana-Farber Cancer Institute | 2011-12-01 |
| Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) (NCT01168921) | M.D. Anderson Cancer Center | 2010-11-03 |
| Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL) (NCT01675102) | European Society for Blood and Marrow Transplantation | 2010-08-01 |
| Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (NCT01199575) | University of California, San Diego | 2010-08-01 |
| Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) (NCT01191190) | Januario Castro, M.D. | 2010-08-01 |
| Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL) (NCT01397916) | Tampere University Hospital | 2010-02-01 |
| A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue (NCT00792077) | M.D. Anderson Cancer Center | 2008-11-01 |
| Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) (NCT00628238) | Chronic Lymphocytic Leukemia Research Consortium | 2008-02-01 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL (NCT00546793) | Gilead Sciences | 2008-01-01 |
| Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older (NCT00535873) | M.D. Anderson Cancer Center | 2007-10-01 |
| Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders (NCT00533923) | Beth Israel Deaconess Medical Center | 2002-12-01 |
| Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia (NCT00021749) | Genta Incorporated | 2001-01-01 |
| Allogeneic Transplantation From Related Haploidentical Donors (NCT00185692) | Stanford University | 2000-08-01 |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders (NCT00636909) | Beth Israel Deaconess Medical Center | 1999-07-01 |